The Influence of Personality on Pulmonary Fibrosis and Sarcoidosis

NCT00504621 | Completed

• 1 other identifier: MEC 07-4-015
• Study Type: observational
• Target: 450
• Locations: 0 countries
• Sites: N/A

Brief Summary

A number of studies have shown that the quality of life of two common interstitial lung diseases (ild), sarcoidosis and pulmonary fibrosis patients, is impaired and that fatigue is a substantial problem for those patients. Furthermore, breathlessness is an additional major problem in pulmonary fibrosis. In the field of cardiovascular disease and breast cancer, personality factors have shown to play a role in patient's morbidity, mortality, quality of life, fatigue, depressive symptoms, and one study showed a predictive role of personality factors in health care consumption. No studies examining personality factors have been performed in sarcoidosis or pulmonary fibrosis. Therefore, the aim of the present study is to examine the role of personality factors as predictors of fatigue, quality of life, prognosis, and health care consumption in sarcoidosis and pulmonary fibrosis. In this study a number of possible moderators, such as social support, will also be examined, aiming to get a full picture of the relationship between the various factors examined. Known and new sarcoidosis and pulmonary fibrosis patients (inclusion period 1 year) of ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht will be asked to participate through completing questionnaires at baseline and every six months for 18 months, and allowing the researchers access to their medical records for the purpose of this study.

Conditions

Sarcoidosis; Pulmonary Fibrosis

Keywords

personality; fatigue; quality of life; health care consumption

Outcome Measures

Primary Outcomes (1)

• The role of personality factors as predictors in sarcoidosis and pulmonary fibrosis.

  The role of personality factors as predictors of fatigue, quality of life, prognosis, and health care consumption in sarcoidosis and pulmonary fibrosis.

  18 months

Study Arms (2)

sarcoidosis

Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009

pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Sarcoidosis patients diagnosed according to WASOG guidelines and IPF patients diagnosed according ATS guidelines.

You may qualify if:

• Patients have to be diagnosed with sarcoidosis based on consistent clinical features and BAL fluid analysis results, according to the WASOG guidelines.
• The diagnosis IPF will be made based on the ATS guidelines

You may not qualify if:

• Poor expression in the Dutch language
• Relevant co morbidity such as a malignancy, dementia, and a history of psychiatric illness

Sponsors & Collaborators

• Maastricht University Medical Center: lead
• Tilburg University: collaborator

Related Publications (1)

• Elfferich MD, De Vries J, Drent M. Type D or 'distressed' personality in sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul;28(1):65-71.

  PMID: 21796893 RESULT

MeSH Terms

Conditions

Sarcoidosis; Pulmonary Fibrosis; Fatigue

Condition Hierarchy (Ancestors)

Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Marjolein Drent, Md, PhD

  Maastricht University

  STUDY CHAIR

• Jolanda de Vries, PhD

  Tilburg University

  STUDY CHAIR

• Marjon Elfferich, MSc

  Gelderse Vallei Ziekenhuis Ede

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 19, 2007
• First Posted: July 20, 2007
• Study Start: August 1, 2007
• Primary Completion: October 1, 2008
• Study Completion: January 1, 2009
• Last Updated: March 26, 2014

Record last verified: 2014-03